Technical analysis of Greenwich LifeSciences, Inc. (GLSI): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials.
Price Performance
| 1 month | -9.44% |
| 3 months | -33.15% |
| Year-to-date | -25.61% |
| 1 year | +40.18% |
| 3 years | +74.64% |
52-Week Range
| 52-week High | $34.10 |
| 52-week Low | $7.78 |
| Avg Volume (90d) | 146K |
Technical Indicators
| SMA 50 | $15.95 |
| SMA 200 | $21.37 |
| Beta | 1.53 |
| 30-day Volatility (annualised) | 86.2% |
| Price vs SMA 50 | -2.0% |
| Price vs SMA 200 | -26.9% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $9.21 | |
| 2025-11 | $8.73 | -5.2% |
| 2025-12 | $21.01 | +140.7% |
| 2026-01 | $30.07 | +43.1% |
| 2026-02 | $27.72 | -7.8% |
| 2026-03 | $24.02 | -13.3% |
| 2026-04 | $23.62 | -1.7% |
| 2026-05 | $26.18 | +10.8% |
| 2026-06 | $23.46 | -10.4% |
| 2026-07 | $13.50 | -42.5% |
| 2026-08 | $14.95 | +10.7% |
| 2026-09 | $15.63 | +4.5% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | $0.05 | $88M |
| 2026-09-15 | | |
| 2026-09-15 | $0.14 | $2.28B |
| 2026-09-15 | | |
Price
| Price | $15.63 |
| Market Cap | $229M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 71.02 |
| EV / EBITDA | -10.05 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 1.54 |